Lyme Disease Treatment Market Size, Growth, Trends, Forecast 2021-2030
The global lyme disease treatment market size is expected to hit around US$ 3 billion by 2030 from at US$ 1.6 billion in 2020, expanding grpwth at a CAGR of 5.9% from 2021 to 2030.
Lyme disease is the most common vector-borne disease. Climate is one of the many important factors that influences the transmission, distribution, and incidence of Lyme disease. Additionally, climate change leads to rise in the survival and activity period of ticks, and increases in the potential risk of Lyme disease. Other factors that affect the number of Lyme disease cases are changes in the population of host species (particularly deer), which affect tick population size.
The incidence of Lyme disease in the U.S. has nearly doubled since 1991, from 3.74 reported cases per 100,000 people to 7.95 reported cases per 100,000 in 2014. According to the Centers for Disease Control and Prevention, 20,000 to 30,000 confirmed cases of Lyme disease have been reported in the U.S. per year. Lyme disease is most common in New Hampshire, Maine, and Vermont, which have experienced the largest increase in reported case rates since 1991.
According to the World Health Organization, the number of cases in Europe has increased steadily; more than 360,000 cases having been reported over the past two decades. According to the Westgate Pet Clinic, 5% to 15% canines are infected by Lyme disease. Hence, rise in prevalence of Lyme disease in both animals and humans is anticipated to boost the growth of the global market.
Report Scope
In terms of test type, the global Lyme disease treatment market has been bifurcated into medication and tick removal. The medication segment is expected to dominate the global Lyme disease treatment market from 2021 to 2030. A range of FDA-approved medications such as antibiotics and NSAIDs are available to treat the early stage Lyme disease. This drives the segment. The antibiotics sub-segment is projected to lead the medication segment during the forecast period. Patients with Lyme disease usually recover rapidly and completely with appropriate antibiotics in the early stages. This contributes to the growth of the sub-segment. Cephalosporin, tetracycline, and macrolides antibiotics are commonly prescribed for the treatment of Lyme disease.
Based on route of administration, the global Lyme disease treatment market has been divided into oral, injectable, and topical. The oral segment is likely to grow at a higher CAGR from 2021 to 2031. The availability of products administered through oral route is projected to drive the segment. Physicians recommend doxycycline as the preferred agent for oral treatment of Lyme disease, due to its activity against other tick-borne illnesses.
In terms of distribution channel, the global Lyme disease treatment market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is projected to lead the global Lyme disease treatment market during the forecast period. The preference for distribution through retail pharmacy is anticipated to propel the segment.
Based on Region, North America is expected to account for a significant share of the global Lyme disease treatment market during the forecast period. The growth of the Lyme disease treatment market in the region can be attributed to rise in access to healthcare and increase in incidence of Lyme disease.
The market in Asia Pacific is likely to expand at a high CAGR from 2021 to 2030. The emergence of vector borne diseases in the region is projected to boost the growth of the market in the region. An article published in the National Library of Medicine stated that the prevalence rate of Lyme disease in northeast China was 1% to 4%. Moreover, rise in awareness about emerging tick-borne pathogens is anticipated to fuel the growth of the global market over the next few years.
Key Players
The report provides profiles of leading players operating in the global Lyme disease treatment market. These include GlaxoSmithKline plc, Pfizer, Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Almirall, LLC, Mayne Pharma, Boehringer Ingelheim International GmbH, Galderma Laboratories, L.P., Lupin Pharmaceuticals, Inc., Chartwell Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Perrigo Company plc, Orion Corporation, and Amneal Pharmaceuticals LLC.
Global Lyme Disease Treatment Market: Segmentation
Market By Treatment Type
Market By Type of Bacteria
Market By Route of Administration
Market By Application
Market By Distribution Channel
Market By Region
This report focuses on lyme disease treatment market includes crucial information on market share, market size, and growth rate for the forecast period 2021 to 2030 at the global level, regional level and company level. From a global perspective, this report represents overall lyme disease treatment market size by analyzing historical data and future prospect. The study highlights deep analysis on the major drivers of the market, restraints, and challenges to help the business owners, suppliers, and marketing personnel in planning effective strategies for the forecast period. This will help the business and manufacturers to lead the market and gain prominent position in future. The report also presents vital information through graphical representation on factors like table, charts, and statistics. The study includes drivers and restraints of the global lyme disease treatment market.
The research not only conducts forecasts in terms of value, but also evaluates the market on the basis of essential parameters, such as Year-on-Year (Y-o-Y) growth. This helps providers to recognize the future opportunities as well predictability of the market.
In order to understand and assess opportunities in this market, the report is categorically divided into five key sections on the basis of segments. The report analyzes the global market in terms of value (US$ dollers) and volume (Million Units).
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2030. Every segment is further sub-segmented into several sub-segmented that are deeply analyzed by experts to offer valuable information to the buyers and market players. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Major Key Points Covered in Report:
Executive Summary: It includes key trends of the lyme disease treatment market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the lyme disease treatment market based on production and revenue.
Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.
Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Lyme disease treatment market.
Market Segments: This part of the report discusses about product, application and other segments of the lyme disease treatment market based on market share, CAGR, market size, and various other factors.
Research Methodology: This section discusses about the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.
Regional Analysis
The research report includes a detailed study of regions of North America, Europe, China, Japan and Rest of the World. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2017 to 2030. These analyses will help the reader to understand the potential worth of investment in a particular region.
The report provides in-depth segment analysis of the global lyme disease treatment market, thereby providing valuable insights at macro as well as micro levels. Analysis of major countries, which hold growth opportunities or account for significant share has also been included as part of geographic analysis of the lyme disease treatment market.
The report includes country-wise and region-wise market size for the period 2017-2030. It also includes market size and forecast by segments in terms of production capacity, price and revenue for the period 2017-2030.
Competitive Landscape and Market Share Analysis
The lyme disease treatment market competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, lyme disease treatment sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2017-2020, this study provides the lyme disease treatment sales, revenue and market share for each player covered in this report.
Research Methodology
The research methodology adopted by analysts for compiling the global lyme disease treatment market report is based on detailed primary as well as secondary research. With the help of in-depth insights of the market-affiliated information that is obtained and legitimated by market-admissible resources, analysts have offered riveting observations and authentic forecasts for the global market.
During the primary research phase, analysts interviewed market stakeholders, investors, brand managers, vice presidents, and sales and marketing managers. Based on data obtained through interviews of genuine resources, analysts have emphasized the changing scenario of the global market.
For secondary research, analysts scrutinized numerous annual report publications, white papers, market association publications, and company websites to obtain the necessary understanding of the global lyme disease treatment market.
The study objectives of this report are:
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Lyme Disease Treatment Market, By Treatment Type
7.1. Lyme Disease Treatment Market, by Treatment Type, 2021-2030
7.1.1. Medication
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Tick Removal
7.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Lyme Disease Treatment Market, By Type of Bacteria
8.1. Lyme Disease Treatment Market, by Type of Bacteria, 2021-2030
8.1.1. Borrelia burgdorferi
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Borrelia mayonii
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Borrelia afzelii
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Borrelia garinii
8.1.4.1. Market Revenue and Forecast (2016-2030)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Lyme Disease Treatment Market, By Route of Administration
9.1. Lyme Disease Treatment Market, by Route of Administration, 2021-2030
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Injectable
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. Topic
9.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 10.Global Lyme Disease Treatment Market, By Application
10.1. Lyme Disease Treatment Market, by Application, 2021-2030
10.1.1. Humans
10.1.1.1. Market Revenue and Forecast (2016-2030)
10.1.2. Animals
10.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 11.Global Lyme Disease Treatment Market, By Distribution Channel
11.1. Lyme Disease Treatment Market, by Distribution Channel, 2021-2030
11.1.1. Hospital Pharmacies
11.1.1.1. Market Revenue and Forecast (2016-2030)
11.1.2. Retail Pharmacies
11.1.2.1. Market Revenue and Forecast (2016-2030)
11.1.3. Online Pharmacies
11.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 12.Global Lyme Disease Treatment Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.1.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.1.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.1.4. Market Revenue and Forecast, by Application (2016-2030)
12.1.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.1.6. U.S.
12.1.6.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.1.6.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.1.6.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.1.6.4. Market Revenue and Forecast, by Application (2016-2030)
12.1.6.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.1.7. Rest of North America
12.1.7.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.1.7.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.1.7.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.1.7.4. Market Revenue and Forecast, by Application (2016-2030)
12.1.7.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.2.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.2.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.2.4. Market Revenue and Forecast, by Application (2016-2030)
12.2.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.2.6. UK
12.2.6.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.2.6.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.2.6.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.2.6.4. Market Revenue and Forecast, by Application (2016-2030)
12.2.6.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.2.7. Germany
12.2.7.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.2.7.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.2.7.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.2.7.4. Market Revenue and Forecast, by Application (2016-2030)
12.2.7.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.2.8. France
12.2.8.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.2.8.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.2.8.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.2.8.4. Market Revenue and Forecast, by Application (2016-2030)
12.2.8.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.2.9. Rest of Europe
12.2.9.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.2.9.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.2.9.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.2.9.4. Market Revenue and Forecast, by Application (2016-2030)
12.2.9.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.3.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.3.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.3.4. Market Revenue and Forecast, by Application (2016-2030)
12.3.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.3.6. India
12.3.6.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.3.6.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.3.6.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.3.6.4. Market Revenue and Forecast, by Application (2016-2030)
12.3.6.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.3.7. China
12.3.7.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.3.7.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.3.7.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.3.7.4. Market Revenue and Forecast, by Application (2016-2030)
12.3.7.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.3.8. Japan
12.3.8.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.3.8.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.3.8.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.3.8.4. Market Revenue and Forecast, by Application (2016-2030)
12.3.8.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.3.9. Rest of APAC
12.3.9.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.3.9.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.3.9.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.3.9.4. Market Revenue and Forecast, by Application (2016-2030)
12.3.9.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.4.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.4.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.4.4. Market Revenue and Forecast, by Application (2016-2030)
12.4.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.4.6. GCC
12.4.6.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.4.6.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.4.6.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.4.6.4. Market Revenue and Forecast, by Application (2016-2030)
12.4.6.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.4.7. North Africa
12.4.7.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.4.7.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.4.7.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.4.7.4. Market Revenue and Forecast, by Application (2016-2030)
12.4.7.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.4.8. South Africa
12.4.8.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.4.8.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.4.8.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.4.8.4. Market Revenue and Forecast, by Application (2016-2030)
12.4.8.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.4.9. Rest of MEA
12.4.9.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.4.9.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.4.9.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.4.9.4. Market Revenue and Forecast, by Application (2016-2030)
12.4.9.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.5.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.5.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.5.4. Market Revenue and Forecast, by Application (2016-2030)
12.5.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.5.6. Brazil
12.5.6.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.5.6.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.5.6.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.5.6.4. Market Revenue and Forecast, by Application (2016-2030)
12.5.6.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
12.5.7. Rest of LATAM
12.5.7.1. Market Revenue and Forecast, by Treatment Type (2016-2030)
12.5.7.2. Market Revenue and Forecast, by Type of Bacteria (2016-2030)
12.5.7.3. Market Revenue and Forecast, by Route of Administration (2016-2030)
12.5.7.4. Market Revenue and Forecast, by Application (2016-2030)
12.5.7.5. Market Revenue and Forecast, by Distribution Channel (2016-2030)
Chapter 13. Company Profiles
13.1. GlaxoSmithKline plc
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Pfizer, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Novartis AG
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche Ltd.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Almirall
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. LLC
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Mayne Pharma
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Boehringer Ingelheim International GmbH
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Galderma Laboratories
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. L.P.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers